<DOC>
	<DOCNO>NCT01474135</DOCNO>
	<brief_summary>This double-masked , randomize , control study assess safety ocular hypotensive efficacy two AR 12286/travoprost fixed-dose combination product compare Travatan® Z patient elevate intraocular pressure</brief_summary>
	<brief_title>AR-12286 Fixed Dose Combination Lower Elevated Intraocular Pressure</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<criteria>1 . 18 year age great . 2 . Diagnosis open angle glaucoma ( OAG ) ocular hypertension ( OHT ) . 3 . Unmedicated ( postwashout ) IOP ≥ 24 mm Hg 2 eligibility visit ( 08:00 hr ) , 27 day apart . At second eligibility visit , IOP &gt; 22 mmHg 10:00 , 12:00 16:00 hr . 4 . Corrected visual acuity eye +1.0 logMAR good ETDRS eye ( equivalent 20/200 ) . 5 . Able willing give sign informed consent follow study instruction . Ophthalmic ( either eye ) : 1 . Glaucoma : pseudoexfoliation pigment dispersion component , history angle closure . Note : Previous laser peripheral iridotomy acceptable . 2 . Intraocular pressure &gt; 36 mm Hg 3 . Known hypersensitivity travoprost , component formulation ( benzalkonium chloride , etc . ) , topical anesthetic . 4 . Previous glaucoma intraocular surgery glaucoma laser procedure study eye ( ) . 5 . Refractive surgery study eye ( ) ( e.g. , radial keratotomy , PRK , LASIK , etc. ) . 6 . Ocular trauma within past six month , ocular surgery laser treatment within past three month . 7 . History evidence ocular infection , inflammation , clinically significant blepharitis conjunctivitis baseline ( Visit 1 ) , herpes simplex keratitis 8 . Contact lens wear within 30 minute instillation study medication . 9 . Ocular medication kind within 30 day Visit 1 , exception ) ocular hypotensive medication ( must wash accord provided schedule ) , b ) lid scrub ( may use prior , Visit 1 ) c ) lubricate drop dry eye ( may use throughout study ) . 10 . Clinically significant ocular disease ( e.g . corneal edema , uveitis , severe keratoconjunctivitis sicca ) might interfere study , include glaucomatous damage severe washout ocular hypotensive medication one month judge safe ( i.e. , cupdisc ratio &gt; 0.8 ) . 11 . Central corneal thickness great 600 µ . 12 . Any abnormality prevent reliable applanation tonometry either eye . Systemic : 13 . Clinically significant abnormality laboratory test screen . 14 . Clinically significant systemic disease ( e.g. , uncontrolled diabetes , myasthenia gravis , hepatic , renal , endocrine cardiovascular disorder ) might interfere study . 15 . Participation investigational study within past 30 day . 16 . Changes systemic medication could substantial effect IOP within 30 day prior screen , anticipate study . 17 . Due status nonclinical safety program , woman childbearing potential pregnant , nursing , plan pregnancy , use medically acceptable form birth control . An adult woman consider childbearing potential unless one year postmenopausal three month postsurgical sterilization . All female childbearing potential must negative urine pregnancy test result screen examination must intend become pregnant study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>Ocular Hypertension</keyword>
</DOC>